Skip to main content

Table 3 Some approved COVID-19 vaccines with their developer, origin, type, dosage and storage conditions

From: Current challenges in different approaches to control COVID-19: a comprehensive review

Name of the vaccine

Developer

Developer country

Vaccine type

No. of doses

Efficacy (%)

Storage (°C)

References

BNT162b2 (Comirnaty)

Pfizer-BioNtech

USA and Germany

mRNA

IM (2)

95

− 80 to – 60

Polack et al. (2020)

mRNA-1273 (Moderna COVID-19 Vaccine)

Moderna

USA

mRNA

IM (2)

94.0

− 25 to − 15

Baden et al. (2021)

Ad26.COV2.S (Janssen COVID-19 vaccine)

Janssen Pharmaceuticals

USA and Germany

Viral vector

IM 1

81.7

2–8

Sadoff et al. (2021)

ChAdOx1 nCoV-19 (AZD-1222) (Covishield)

Oxford-AstraZeneca

UK, Sweden and India

Viral vector

IM (2)

81

2–8

Voysey et al. (2021)

Sputnik V

Gamaleya Research Institute

Russia

Viral vector

IM (2)

91.6

2–8

Logunov et al. (2021)

BBV152 (Covaxin)

Bharat Biotech

India

Inactivated

IM (2)

78

2–8

Ella et al. (2021)

CronaVac

Sinovac

China

Inactivated

IM (2)

50.4

2–8

Zhang et al. (2021)

BBIBP-CorV

Sinopharm

China

Inactivated

IM (2)

79.3

2–8

Xia et al. (2021)

NVX-CoV2373

Novavax

USA

Protein subunit

IM (2)

96

2–8

Shinde et al. (2021)

CVnCoV

CureVac

Germany

mRNA

IM (2)

48.2

2–8

Hadj Hassine (2021)

AD5-nCOV (Convidecia)

CanSino Biologics

China

Viral vector

IM, IN (1)

63

2–8

Wu et al. (2021)

SCB-2019

Clover Biopharmaceu ticals

China

Protein subunit

IM

67

2–8

Bravo et al. (2022)

ZyCoV-D

Cadila Healthcare

India

DNA plasmid

ID (3)

66.6

2–8

Chavda et al. (2021)

ZF2001 (Zifivax)

Anhui Zhifei Longcom

China

Protein subunit

IM (3)

82

2–8

Yang et al. (2021)

  1. IM intramuscular, IN intranasal, ID intradermal